NCT06040125 Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
| NCT ID | NCT06040125 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | PROSTATE CANCER |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-08-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-01-01 with a primary completion date of 2026-08-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will improve frailty and sarcopenic status and disease progression outcomes among pre-frail/frail metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). The names of the study intervention involved in this study is: • Supervised circuit training (aerobic and resistance exercise regimen)
Eligibility Criteria
Inclusion Criteria: * Ability to understand and the willingness to sign informed consent prior to any study-related procedures. * Diagnosed with metastatic prostate cancer. * Aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included. * Have been receiving androgen deprivation (either with or without androgen receptor targeted treatment) for at least one month and expect to remain on their treatment for at least 4 months. * Are pre-frail or frail as indicated by the FRAIL scale (a score of 1-2 = pre-frail; 3-5 = frail). * Have physician's clearance to participate in exercise. * Speak English. * Participate in less than 2 structured resistance exercise sessions per week over the last 4 months. * Participate in less than or equal to 60 minutes of moderate-to-vigorous aerobic exercise per week over the last month. * Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions. Exclusion Criteria: * Receiving chemotherapy. This study is exclusively targeting androgen deprivation therapy-related effects. * Have unstable bone lesions. In general patients with severely symptomatic/unstable bone lesions due to bone metastases are at a higher risk of fractures. * Complete 2 or more structured resistance exercise sessions per week over the last 4 months and participate in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current exercise program. * Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded. * Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting androgen deprivation therapy-related effects. * Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.
Contact & Investigator
Christina Dieli-Conwright, MD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06040125 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying PROSTATE CANCER. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06040125 currently recruiting?
Yes, NCT06040125 is actively recruiting participants. Contact the research team at ChristinaM_Dieli-Conwright@dfci.harvard.edu for enrollment information.
Where is the NCT06040125 trial being conducted?
This trial is being conducted at Boston, United States, Boston, United States, Boston, United States.
Who is sponsoring the NCT06040125 clinical trial?
NCT06040125 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Christina Dieli-Conwright, MD at Dana-Farber Cancer Institute. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.